Cylembio is a therapeutic cancer vaccine candidate that targets cells and immune-suppressive cells in the tumor microenvironment through activation and expansion of T cells against IDO1 and/or PD-L1 ...

Ianalumab added to eltrombopag significantly prolonged the time to treatment failure (TTF) in adults with primary immune thrombocytopenia (ITP), a B cell-driven autoimmune disease, according to phase ...

Approved in 2022, Skysona is indicated to slow the progression of neurologic dysfunction in boys 4 to 17 years of age with early, active cerebral adrenoleukodystrophy.

On July 29, he was removed from his role after some conservative figures such as far-right activist and conspiracy theorist Laura Loomer criticized his approach to drug approvals and his past ...

Forty-six point four percent said they would accept one or more missing vaccines if they could be provided during their ED visit.

HealthDay News — Few patients with myelodysplastic syndromes (MDS) receive treatment with hypomethylating agents (HMAs), with evidence of age-, sex-, and race-related disparities, according to a study ...

Discordance was greater for middle-aged adults, racial and ethnic minorities, and for those with lower educational attainment.

The KEYNOTE-905 study is ongoing and will evaluate other endpoints including EFS, OS, and pCR rate for neoadjuvant and adjuvant pembrolizumab vs surgery alone.